United States : Micromet and Sanofi-aventis Sign Global Collaboration and License Agreement for New Solid Tumor BiTE Antibody.Byline: pinto pinto Spotted horse, also called paint, piebald, skewbald, and other terms to describe variations in colour and markings. The American Indian ponies of the western U.S. were often pintos. Most pure-breed associations refuse to register horses with pinto colouring. 03 Micromet, Inc. and sanofi-aventis announced a global collaboration and license agreement to develop a BiTE(R) antibody against an antigen present at the surface of carcinoma cells. BiTE antibodies are novel therapeutic antibodies that activate a patient's T cells T cells A type of white blood cell produced in the thymus gland. T cells are an important part of the immune system. Infants born with an underdeveloped or absent thymus do not have a normal level of T cells in their blood. to seek out and destroy cancer cells cells once believed to be peculiar to cancers, but now know to be epithelial cells differing in no respect from those found elsewhere in the body, and distinguished only by peculiarity of location and grouping. See also: Cancer . Anzeige Under this agreement, Micromet will be mainly responsible for the discovery, research and development of the BiTE antibody through the completion of phase 1 clinical trials phase 1 clinical trial Phase 1 study. See Phase study. under the supervision of a Joint Steering Committee steer·ing committee n. A committee that sets agendas and schedules of business, as for a legislative body or other assemblage. steering committee Noun . Sanofi-aventis will then have the full responsibility for the further development, as well as for the worldwide commercialization of the BiTE antibody. Under the terms of the agreement, sanofi-aventis agreed to pay Micromet an upfront cash payment of 8 million euros (approx. US$ 12 million) following signing of the agreement. Micromet is eligible for development and regulatory milestone payments of up to 162 million euros (approx. US$ 241 million), plus performance-based sales milestones of up to 150 million euros (approx. US$ 224 million) and royalties on worldwide product sales. Copyright : Euclid Infotech Pvt. Ltd. Provided by Syndigate.info an Albawaba.com company |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion